TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Señales de momentum (gestores comparables):
amplitud de titulares -4.5% ·
flujo de acciones -8.7% ·
nuevas posiciones netas -4.8%
— fórmula
Distribución amplia — caída de acciones y menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | — | — |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | — | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | — | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | — |
| Q2 2024 | 19 | — | 61.88M | $1.01B | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasivo) | 19.41M | — | $427.89M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (pasivo) | 9.28M | +5.6% | $203.64M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Duquesne Family Office ✦ | 9.00M | +530.1% | $198.30M | 5.6% | ▲ Add | 2 | SEC ↗ |
| 4 | Glenview Capital ✦ | 8.46M | 0.0% | $186.38M | 4.7% | Held | 3 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 6.99M | -53.1% | $154.07M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 6.98M | -14.0% | $153.76M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 7 | Millennium Management ✦ | 6.54M | -44.6% | $144.19M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 8 | Viking Global Investors ✦ | 6.50M | -14.1% | $143.34M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 9 | Marshall Wace ✦ | 5.16M | +87.8% | $113.63M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 2.51M | -31.3% | $55.30M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 2.39M | -31.2% | $52.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 2.05M | +148.3% | $45.17M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 13 | Norges Bank ✦ (pasivo) | 1.75M | +15.4% | $38.55M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 1.20M | -66.9% | $26.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 686.46K | -4.0% | $15.13M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Greenlight Capital (DME Capital) ✦ | 468.55K | +44.2% | $10.33M | 0.5% | ▲ Add | 3 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 185.91K | +2.1% | $4.10M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 18 | GAMCO Investors ✦ | 105.60K | -18.6% | $2.33M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 19 | ARK Investment Management ✦ | 100.44K | -18.9% | $2.21M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 19.22K | +9.4% | $423,675 | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 21 | Bridgewater Associates ✦ | 9.39K | -59.5% | $207,022 | 0.0% | ▼ Trim | 3 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Point72 Asset Management | $9.33M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 646 tenedores, 666.61M acciones, $16.70B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 2.52K acc. · $98,841
Director · 367.60K acc. · $14.36M
Officer · 4.50K acc. · $174,221
Officer · 314 acc. · $12,153
Officer · 2.50K acc. · $94,077
Director · 415 acc. · $15,459
Officer · 6.95K acc. · $261,224
Officer · 18.60K acc. · $680,291
Director · 17 acc. · $593
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología